FDA warns JW Nutritional over serious CGMP failures in OTC drug manufacturing, including untested components and inadequate microbial limits.
What happened
FDA inspected JW Nutritional's drug manufacturing facility in McKinney, TX, from September 22 to 26, 2025. FDA found that the company did not test each incoming component lot for identity and did not validate its production process. FDA also found microbiological release specifications for an OTC drug product were based on food and supplement standards rather than USP drug standards.
What FDA found
The firm did not test each shipment of each incoming component lot for identity, including a USP limit test for high-risk impurities.
21 CFR 211.84(d)(2)The firm did not validate its production process before commercial distribution.
21 CFR 211.100(a)The firm did not adequately qualify its (b)(4) system used as a drug component and to clean equipment, including needed microbial monitoring.
21 CFR 211.100(a)The firm used food and supplement microbial standards for an OTC drug product instead of USP <61> and <62> drug standards.
21 CFR 211.160(b)The firm's microbial specification allowed much higher total plate count and yeast/mold limits than generally accepted for drug products and omitted testing for (b)(4).
21 CFR 211.160(b)
What FDA wants
FDA asks the company to correct the violations promptly and respond in writing within 15 working days, including component test results within 30 calendar days, a risk assessment, and plans for testing, validation, and microbiological controls.
Who should pay attention
- brands that use JW Nutritional as a contract drug manufacturer
- companies buying OTC drug products made by JW Nutritional
- suppliers and distributors of OTC drug components
This is a summary. Read the original letter on fda.gov.